- Pharmacists engage with patients in campaign for improved nutrition
- Report: More than a quarter of U.S. kids take at least one chronic med
- FDA approves Merck's Gardasil for prevention of anal cancer
- RediClinic's weight-loss program builds on current convenient care offerings
- Merck's hepatitis C drug granted priority review by FDA
SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for obesity in adults, the agency said Wednesday.
The FDA announced the approval of Arena Pharmaceuticals' Belviq (lorcaserin hydrochloride), designed for use alongside reduced-calorie diets and exercise, for chronic weight management. Eisai will distribute the drug.
"Obesity threatens the overall well-being of patients and is a major public health concern," FDA Center for Drug Evaluation and Research director Janet Woodcock said. "The approval of this drug, used responsibly in combination with a healthy diet and lifestyle, provides a treatment option for Americans who are obese or are overweight and have at least one weight-related comorbid condition."
The drug works by activating the brain's serotinin 2C receptor, which is believed to help people eat less and feel full after eating smaller amounts of food.